abstract |
An agent for inhibiting the activity of inositol-1,4,5-triphospate receptor subtype 3 (IP 3 R3), containing caffeine and/or its analogs, and/or their pharmaceutically acceptable salts, as an active ingredient, is provided. A composition for preventing and/or treating a disease associated with Ca 2+ release through IP 3 R3, containing the IP 3 R3 inhibiting agent, is also provided. |